Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's edition of Five Must-Know Things: another acquisition for AbbVie; Roche buys into the obesity market; J&J’s oral immunology push; oral incretins advance; and AstraZeneca on Chinese innovation.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 8 December 2023, including: another acquisition for AbbVie Inc.; Roche Holding AG buys into the obesity market; Johnson & Johnson’s oral immunology push; oral incretins advance; and AstraZeneca PLC on Chinese innovation.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "AbbVie Strikes Again By Teeing Up $8.7bn Offer For Cerevel" - Scrip, 6 Dec, 2023.)
(Also see "Roche Looks To Muscle Into Obesity Market With $2.7bn Carmot Buyout" - Scrip, 4 Dec, 2023.)
(Also see "J&J In Immunology: 'We Plan To Lead The Orals Market'" - Scrip, 6 Dec, 2023.)
(Also see "Time For Oral Incretins To Prove Their Worth" - Scrip, 5 Dec, 2023.)
(Also see "AstraZeneca Likes What Chinese Innovation Has To Offer" - Scrip, 6 Dec, 2023.)